Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the aminopyrimidine class. It is characterized by a pyrimidine core with an ethynyl linkage to a benzyl group and an oxazolone moiety. The compound has been identified as an experimental agent and is not approved for clinical use. Its primary known mechanism of action is inhibition of heat shock protein HSP 90-alpha (HSP90AA1), a molecular chaperone involved in the folding and stabilization of various client proteins implicated in cancer cell growth and survival. No approved indications or advanced clinical development have been reported for this molecule[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-({2-[(2-amino-6-methylpyrimidin-4-yl)ethynyl]benzyl}amino)-1,3-oxazol-2(3H)-one.